Is Wall Street Bullish or Bearish on Insulet Stock?
Analysts' consensus for Insulet (PODD) is 'Moderate Buy' with 13 'Strong Buy' ratings, 2 'Moderate Buy', 11 'Hold', and 1 'Strong Sell'. Citigroup analyst Joanne Wuensch maintained a 'Hold' rating with a $150 price target, a 3.1% upside. The mean price target is $172.46, an 18.6% premium, while the highest target is $275, an 89.1% upside.
How this was made
The 30-second read
Why it matters
Analyst rating adjustments can influence short-term price volatility but lack of new fundamentals limits impact.
Market read
The article offers a modest update on analyst sentiment for PODD with limited trading relevance.
What to watch
No new product or earnings data accompanies the rating change.
Background
Insulet (ticker PODD) is a medical device company specializing in insulin pumps.
Ticker impact
Analyst consensus and price targets for PODD were updated, showing a shift to a moderate buy stance.
Potential modest pullback or sideways movement as investors reassess targets.
No new fundamental data, only analyst opinion change; impact limited.
Market effects
Minor effect on medical device sector sentiment.
Limited to US equity markets.
Low
Counterpoint
Investors may view the consensus shift as an overreaction and hold the stock.
Key entities
- Analyst FirmCitigroup Inc.
Provided a hold rating and $150 price target for PODD.
